425: Penumbra Merger Vote Reminder

Penumbra Inc. urges stockholders to vote FOR the proposed merger with Boston Scientific Corporation, emphasizing the importance of their vote for the upcoming Special Meeting.

Summary

• Penumbra, Inc. is reminding its stockholders about the upcoming Special Meeting on May 6, 2026, where they will vote on the proposed merger with Boston Scientific Corporation.
• The company's Board of Directors unanimously recommends voting FOR the merger and related proposals.
• Stockholders are informed that failing to vote will have the same effect as voting against the merger.
• Two reminder letters were distributed to certain stockholders on April 23, 2026, and expected on April 29, 2026, urging them to vote via the internet, telephone, or by returning a proxy card.
• Proxy materials, including a proxy statement/prospectus, were declared effective on April 1, 2026, and mailed to stockholders on or about April 1, 2026.
• Investors are encouraged to read the proxy statement/prospectus and other SEC filings carefully for important information.
• Free copies of these documents are available on the SEC website (www.sec.gov) and through Penumbra's and Boston Scientific's investor relations departments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily serving as a procedural reminder for a merger vote. While it reiterates the board's recommendation, the need for multiple reminders suggests potential challenges in securing full shareholder participation.

Positives

• The Board of Directors unanimously recommends voting FOR the merger.
• Multiple communication channels (internet, telephone, mail) are provided for voting.
• A dedicated proxy solicitor (Innisfree M&A Incorporated) is available to assist stockholders with questions and voting.

Negatives

• A significant number of stockholders have not yet voted, necessitating reminder letters.
• Failing to vote is explicitly stated as having the same effect as voting against the merger, highlighting a potential risk if voter turnout is low or apathetic.

Risks

• Failure to obtain stockholder approval for the merger.
• Potential litigation related to the proposed transaction that could be instituted against Penumbra or its directors.
• Disruptions from the proposed transaction harming Penumbra's business, including current plans and operations.
• The inability to retain and hire key personnel during the pendency of the transaction.
• Potential adverse reactions or changes to business relationships resulting from the announcement, pendency, or completion of the proposed transaction.
• Uncertainty as to the long-term value of Boston Scientific's common stock.
• Legislative, regulatory, and economic developments affecting Penumbra's business.
• General economic and market developments and conditions.
• Evolving legal, regulatory, and tax regimes under which Penumbra operates.
• Potential business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect Penumbra's financial performance.
• Restrictions during the pendency of the proposed transaction that may impact Penumbra's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism or outbreak of war or hostilities, as well as Penumbra's response to any of the aforementioned factors.

Future Outlook

The filing primarily focuses on the upcoming stockholder vote for the proposed merger with Boston Scientific Corporation. It does not contain specific forward-looking financial guidance beyond the expected closing of the transaction and its potential benefits, which are subject to various risks and uncertainties.

Management Comments

• "Our Board of Directors unanimously recommends that you vote FOR the Merger and related proposals."
• "Please note that failing to vote will have the same effect as a vote against the Merger."
• "Therefore, your vote is very important, regardless of the number of shares you own."
• "If you have not already done so, please vote TODAY via the Internet, telephone, or by signing, dating, and returning the enclosed proxy card or voting instruction form in the envelope provided."
• "YOUR VOTE IS IMPORTANT -- PLEASE VOTE TODAY!"

Industry Context

StockSavvy.ai notes that this filing is a standard communication in the context of a merger and acquisition process, specifically focused on securing stockholder approval. The emphasis on voting reminders is common when a significant portion of shareholders have not yet responded, indicating potential challenges in achieving the required turnout or approval thresholds for the transaction.

Legal Proceedings

• Potential litigation relating to the proposed transaction that could be instituted against the Company or its directors.

Stakeholder Impact

• Shareholders: Their vote is crucial for the approval of the merger. Failure to vote is equivalent to voting against the merger. The long-term value of their investment depends on the successful completion of the merger and the future performance of Boston Scientific.
• Employees: The merger may lead to changes in employment, roles, and benefits. Uncertainty exists regarding retention of key personnel.
• Business Relationships: Potential adverse reactions or changes to existing business relationships with suppliers, customers, and partners due to the announcement and pendency of the merger.

Next Steps

• Stockholders are urged to vote FOR the merger and related proposals.
• The Special Meeting of Penumbra, Inc. stockholders is scheduled for May 6, 2026.
• The company and Boston Scientific Corporation will continue to file necessary documents with the SEC related to the merger.

Key Dates

Recommendation

This filing is a procedural reminder for a merger vote and does not contain new financial performance data or strategic updates that would warrant a change in investment recommendation. Investors should refer to the definitive proxy statement/prospectus for detailed information regarding the merger and its implications.

Keywords

Penumbra Inc., Boston Scientific Corporation, Merger, Acquisition, Stockholder Meeting, Proxy, SEC Filing, Form 425, Special Meeting, Vote